摘要
目的评价美金刚联合多奈哌齐治疗的中、重度阿尔茨海默病(AD)的疗效及安全性。方法本研究为回顾性调查研究,共有符合标准的98例AD患者参与本研究,研究组56例,对照组42例,研究组患者在服用盐酸多奈哌齐的基础上加用盐酸美金刚,对照组患者仍单用盐酸多奈哌齐,对比治疗前及治疗12周末疗效,采用严重障碍量表(SIB)评价认知功能,日常生活能力量表(ADL)评价日常生活活动能力,药物副反应采用药物副作用量表(TESS)评价不良反应。结果 12周后研究组SIB增分较对照组更显著(64.4±3.56 vs.59.5±3.18,t=5.717,P<0.01)、ADL减分有统计学差异(30.4±2.74 vs.28.8±2.78,t=2.087,P=0.046)。2组间不良反应差异无统计学意义。结论美金刚能使对已经使用多奈哌齐治疗中、重度AD患者进一步获益,且安全性好。
Objective To evaluate the efficacy and safety of memantine in patients with moderate to severe Alzheimers disease （AD） already receiving stable treatment with donepezil. Methods This was a retrospective study. Ninty-eight pa- tients participated , the control group received donepezil as usual, the study group received memantine additionally （start- ing dose at 5 mg/d,5 mg weekly increments,20 mg/d after 4 weeks）on the basis of donepezil . All were treated for 12 weeks. Severe Impairment Battery （SIB） and Activities of Daily Living Inventory （ADL） were used to evaluate the cogni- tion and activities of daily living. Results The baseline of SIB and ADL were same between the two groups;after 12 weeks, SIB and ADL of study group changed greatly, and the changes were larger than that of control group. During the course, the adverse reactions were all light of the two groups. Conclusion In patients with moderate to severe AD receiv- ing stable doses of donepezil, memantine had better efficacy and safety.
出处
《中华全科医学》
2014年第5期755-757,共3页
Chinese Journal of General Practice
关键词
美金刚
多奈哌齐
阿尔茨海默病
疗效
Memantine
Donepezil
Alzheimers disease
Clinical efficacy
